Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Methoxyamine
2. Methoxyamine Hydrochloride
3. Methoxylamine
1. Methoxyamine
2. 67-62-9
3. Methoxylamine
4. Hydroxylamine, O-methyl-
5. Hydroxylamine Methyl Ether
6. Nci-c60060
7. Ch3onh2
8. 9tzh4wy30j
9. Alpha-methylhydroxylamine
10. Hsdb 2883
11. Einecs 200-660-1
12. Unii-9tzh4wy30j
13. Brn 1098249
14. Methoxy Amine
15. N-methoxyamine
16. Meonh2
17. Nh2ome
18. O-methyl Hydroxylamine
19. O-methyl-hydroxylamine
20. O-methylhydroxyl Amine
21. Spectrum_001650
22. O-methyl Hydroxyl Amine
23. Specplus_000744
24. Spectrum2_000914
25. Spectrum3_000765
26. Spectrum4_001103
27. Spectrum5_001275
28. Methoxyamine [mi]
29. Bspbio_002410
30. Kbiogr_001546
31. Kbioss_002130
32. 4-01-00-01252 (beilstein Handbook Reference)
33. Divk1c_000600
34. Divk1c_006840
35. Methoxyamine [who-dd]
36. Spbio_000788
37. Chembl1213633
38. Dtxsid8043862
39. Gmpkipwjbdourn-uhfffaoysa-
40. Kbio1_000600
41. Kbio1_001784
42. Kbio2_002130
43. Kbio2_004698
44. Kbio2_007266
45. Kbio3_001630
46. Chebi:192842
47. Ninds_000600
48. O-methylhydroxylamine [hsdb]
49. Bbl028003
50. Mfcd00044753
51. Stl373472
52. Akos009087974
53. Db06328
54. Idi1_000600
55. Ncgc00178666-01
56. Bp-31110
57. F16476
58. Q18344129
| Molecular Weight | 47.057 g/mol |
|---|---|
| Molecular Formula | CH5NO |
| XLogP3 | -0.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 0 |
| Exact Mass | 47.037113783 g/mol |
| Monoisotopic Mass | 47.037113783 g/mol |
| Topological Polar Surface Area | 35.2 Ų |
| Heavy Atom Count | 3 |
| Formal Charge | 0 |
| Complexity | 4.8 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in cancer/tumors (unspecified).
Methoyxamine is investigated for use as an adjunct to alkylating agents, reverse resistance to chemotherapy, and enhancing radiation therapy. Methoxyamines proposed mechanism of action is through blocking of the abasic sites (apurinic/apyrimidinic - AP sites) created by the cleavage of base excision repair (BER) glycoslyates. DNA alkylating agents cause cell death through excessive DNA damage by adduct formation. The human mechanism for DNA repair is very efficient and cancer therapeutics which use this mechanism are often ineffective due to resistance by efficient repair mechanisms such as base excision repair (BER). Alkylating agents such as tezmozolomide form methylated DNA adducts such as O6-methylguanine (O6mG), 7-methylguanine (N7mG) and 3-methyladenine (N3mA). O6mG is a cytotoxic and genotoxic adduct which is repaired by O6-methylguanine DNA-methyltransferase (MGMT). O6mGs cytotoxicity is due to the mismatch repair mechanism (MMR), but cell induced defects in this repair pathway can lead to drug resistance. The N7mG (dominant lesions caused by methylating agents) and N3mA adducts are both repaired by the BER mechanism. Methoxyamine disrupts the BER pathway, increasing the amount of cytotoxic adducts, which results in cell death. Methoxyamine inhibits BER by stabilizing the AP sites created by cleavage of BER glysosylates, forming MX-AP lesions. Methoxyamine may be an effective adjunct to iododeoxyuridine(IUdR) induced radiosensitization and radiation treatment. IUdR is a halogenated pyrimidine which is incorporated into cellular DNA instead of thymidine, which enhances radiotumor sensitivity. Methoxyamine is proposed to have a dual action in this treatment as it alters cell cycle kinetics as well as prevents repair of DNA by BER, allowing increased sensitivity of tumor cells to DNA damage by radiation therapy. The efficiency of cell cycle repair has been shown to be cell cycle dependent, with the G1 phase being second most sensitive to ionizing radiation (the mitotic, M, phase is the most sensitive). Methoxyamine increases the amount of protein 53 (P53) and protein Rb (pRB), senescence factors which cause the cell to remain in the G1 phase. Methoxyamine also creates a stringent checkpoint at the G1/S boundary as well as an insufficient checkpoint at the G2 stage, preventing cells from going into the S phase. The increased number of G1 cells makes methoxyamine treated tumors more susceptible to ionizing radiation. The temozolomide and methoxyamine created lesion MX-AP not only disrupts the BER pathway but inhibits topoisomerase II alpha (topo II), an enzyme necessary for DNA replication, recombination and chromosome segregation. MX-AP sites block DNA replication and interfere with choromosome splitting. It is currently uncertain how what the interaction between topoisomerase II and methoxyamine causes cytotoxicity, but several mechanisms have been proposed, such as MX-AP sites binding to topo II, thus reducing their functionality by forming a toxic complex.
THE MAJOR MUTAGENIC EFFECT OF O-METHYLHYDROXYLAMINE ON VEGETATIVE SD PHAGE IN ESCHERICHIA COLI IS PROBABLY DUE TO REPLICATION ERRORS RESULTING FROM INCORPORATION OF ENZYMICALLY MODIFIED PRECURSORS INTO DNA.
BUDOVSKII EI ET AL; THE MECHANISM OF THE MUTAGENIC ACTION OF HYDROXYLAMINE. XIV. O-METHYLHYDROXYLAMINE-INDUCED DIRECT MUTATIONS IN VEGETATIVE SD PHAGE; MUTAT RES 59(2) 285 (1979)
THE DIPHOSPHATE REACTION PRODUCT (MO6A) OF O-METHYLHYDROXYLAMINE WAS PREPARED AND COPOLYMERIZED WITH CYTIDINE DIPHOSPHATE OR ADENOSINE DIPHOSPHATE. THE SPECIFIC CHANGED BASE PAIRING IS PROBABLY CAUSED BY A TAUTOMERIC SHIFT FROM THE AMINO TO THE IMINO. CHANGING THE TAUTOMERIC EQUILIBRIUM OF A PURINE BY A SUBSTITUTION REACTION WITH A MUTAGEN SHOULD BE CONSIDERED AS A CONTRIBUTING FACTOR FOR THE MECHANISM OF MUTATION OF HYDROXYLAMINES.
SINGER B, SPENGLER S; REACTION OF O-METHYLHYDROXYLAMINE WITH ADENOSINE SHIFTS TAUTOMERIC EQUILIBRIUM TO CAUSE TRANSITIONS; FEBS LETT 139(1) 69 (1982)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
44
PharmaCompass offers a list of Methoxyamine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Methoxyamine manufacturer or Methoxyamine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Methoxyamine manufacturer or Methoxyamine supplier.
PharmaCompass also assists you with knowing the Methoxyamine API Price utilized in the formulation of products. Methoxyamine API Price is not always fixed or binding as the Methoxyamine Price is obtained through a variety of data sources. The Methoxyamine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Methoxyamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Methoxyamine, including repackagers and relabelers. The FDA regulates Methoxyamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Methoxyamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Methoxyamine supplier is an individual or a company that provides Methoxyamine active pharmaceutical ingredient (API) or Methoxyamine finished formulations upon request. The Methoxyamine suppliers may include Methoxyamine API manufacturers, exporters, distributors and traders.
Methoxyamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Methoxyamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Methoxyamine GMP manufacturer or Methoxyamine GMP API supplier for your needs.
A Methoxyamine CoA (Certificate of Analysis) is a formal document that attests to Methoxyamine's compliance with Methoxyamine specifications and serves as a tool for batch-level quality control.
Methoxyamine CoA mostly includes findings from lab analyses of a specific batch. For each Methoxyamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Methoxyamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Methoxyamine EP), Methoxyamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Methoxyamine USP).
